Document:

EX-4.5

 Exhibit 4.5 

Dated February 25, 2015 

$81,850,000 
 AMENDMENT
NO. 2 TO TERM LOAN FACILITY 
 FASTNET SHIPCO LLC 

SHANNON SHIPCO LLC 

ROCKALL SHIPCO LLC 
 FORTH
SHIPCO LLC 
 VIKING SHIPCO LLC 

as joint and several Borrowers 

and 
 ARDMORE SHIPPING
CORPORATION 
 ARDMORE SHIPPING LLC 

as joint and several Guarantors 

and 
 DVB BANK SE 

as Original Lender 
 and 

DVB BANK SE 
 as Facility
Agent 
 and 
 DVB BANK SE

 as Security Agent 

SUPPLEMENTAL AGREEMENT 

relating to the refinancing of 

m.t. “Ardmore Seafarer”, m.t. “Ardmore Seamaster” and m.t. “Ardmore Centurion” and the 

financing of hull numbers S-5118 and S-5119 at SPP Shipbuilding Co., Ltd. 

 Index 
  

							
	Clause	 	 	  	Page	 
			
	 1
	 	Definitions and Interpretation	  	 	1	  
	 2
	 	Agreement of the Finance Parties	  	 	2	  
	 3
	 	Conditions Precedent	  	 	2	  
	 4
	 	Representations	  	 	3	  
	 5
	 	Amendments to Facility Agreement and other Finance Documents	  	 	3	  
	 6
	 	Further Assurance	  	 	6	  
	 7
	 	Costs and Expenses	  	 	7	  
	 8
	 	Notices	  	 	7	  
	 9
	 	Counterparts	  	 	7	  
	 10
	 	Governing Law	  	 	7	  
	 11
	 	Enforcement	  	 	7	  
		
	Schedules	  			
		
	 Schedule 1 Conditions Precedent
	  	 	9	  
		
	Execution	  			
		
	 Execution Pages
	  	 	10	  

 THIS AGREEMENT is made on [—] 2015 

PARTIES 
  

	(1)	FASTNET SHIPCO LLC, SHANNON SHIPCO LLC, ROCKALL SHIPCO LLC, FORTH SHIPCO LLC and VIKING SHIPCO LLC, each a limited liability company formed in the Republic of the Marshall Islands whose registered address is at
The Trust Company of the Marshall Islands, Trust Company Complex, Ajeltake Road, Ajeltake Island, Majuro, Marshall Islands MH 96960 as joint and several borrowers (together the “Borrowers” and each a “Borrower”)

  

	(2)	ARDMORE SHIPPING CORPORATION, a corporation incorporated in the Republic of the Marshall Islands whose registered address is at The Trust Company of the Marshall Islands, Trust Company Complex, Ajeltake Road,
Ajeltake Island, Majuro, Marshall Islands MH96960 (“ASC”) 

  

	(3)	ARDMORE SHIPPING LLC, a limited liability company incorporated in the Republic of the Marshall Islands whose registered address is at The Trust Company of the Marshall Islands, Trust Company Complex, Ajeltake
Road, Ajeltake Island, Majuro, Marshall Islands MH96960 (“ASLLC” and together with ASC the “Guarantors”) 

  

	(4)	DVB BANK SE acting through its office at Platz der Republic 6, D-60325 Frankfurt am Main, Federal Republic of Germany as lender (the “Original Lender”) 

 

	(5)	DVB BANK SE as agent of the other Finance Parties (the “Facility Agent”) 

  

	(6)	DVB BANK SE as security agent for the Secured Parties (the “Security Agent”) 

BACKGROUND 
  

	(A)	By the Facility Agreement, the Original Lender agreed to make available to the Borrowers a facility of (originally) up to $81,850,000. 

 

	(B)	This Agreement sets out the terms and conditions on which the Original Lender and the other Finance Parties agree, with effect on and from the Effective Date, at the request of the Obligors, to amend the financial
covenants and to the consequential amendment of the Facility Agreement and the other Finance Documents in connection with those matters. 

OPERATIVE PROVISIONS 
  

	1	DEFINITIONS AND INTERPRETATION 

  

	1.1	Definitions 

 In this Agreement: 

“Effective Date” means the date on which the conditions precedent in Clause 3 (Conditions Precedent) are satisfied.

 “Facility Agreement” means the facility agreement dated 28 September 2012 as amended and restated by an amending and
restating agreement dated 16 June 2014 and made between, amongst others, (i) the Borrowers, (ii) the Guarantors, (iii) the Original Lender, (iv) the Facility Agent, and (v) the Security Agent. 

“Obligor” means the Borrowers and the Guarantors. 

“Party” means a party to this Agreement. 
  

	1.2	Defined expressions 

  

 Defined expressions in the Facility Agreement and the other Finance Documents shall have the same
meanings when used in this Agreement unless the context otherwise requires or unless otherwise defined in this Agreement. 
  

	1.3	Application of construction and interpretation provisions of Facility Agreement 

 Clause
1.2 (construction) and clause 1.4 (agreed forms of Finance Documents) of the Facility Agreement apply to this Agreement as if they were expressly incorporated in it with any necessary modifications. 

 

	1.4	Designation as a Finance Document 

 The Borrowers and the Facility Agent designate this
Agreement as a Finance Document. 
  

	1.5	Third party rights 

 Unless provided to the contrary in a Finance Document, a person who
is not a Party has no right under the Third Parties Act to enforce or to enjoy the benefit of any term of this Agreement. 
  

	2	AGREEMENT OF THE FINANCE PARTIES 

  

	2.1	Agreement of the Original Lender 

 The Original Lender agrees, subject to and upon the
terms and conditions of this Agreement, to a change in the financial covenants of the Facility Agreement. 
  

	2.2	Agreement of the Finance Parties 

 The Finance Parties agree, subject to and upon the
terms and conditions of this Agreement, to the consequential amendment of the Facility Agreement and the other Finance Documents in connection with the matters referred to in Clause 2.1 (Agreement of the Original Lender). 

 

	2.3	Effective Date 

 The agreement of the Original Lender and the other Finance Parties
contained in Clauses 2.1 (Agreement of the Original Lender) and 2.2 (Agreement of the Finance Parties) shall have effect on and from the Effective Date. 
  

	3	CONDITIONS PRECEDENT 

 The agreement of the Original Lender and the other Finance Parties
contained in Clause 2.1 (Agreement of the Original Lender) and 2.2 (Agreement of the Finance Parties) is subject to: 
  

	(a)	no Default continuing on the date of this Agreement and the Effective Date or resulting from the occurrence of the Effective Date; 

  

	(b)	the Repeating Representations to be made by each Obligor being true in all material respects on the date of this Agreement and the Effective Date; 

 

	(c)	the Facility Agent having received all of the documents and other evidence listed in Schedule 1 (Conditions Precedent) in form and substance satisfactory to the Facility Agent on or before [—] 2015 or such later date as the Facility Agent may agree with the Borrowers. 

  
 2 

	4	REPRESENTATIONS 

  

	4.1	Facility Agreement representations 

 Each Obligor that is a party to the Facility
Agreement makes the representations and warranties set out in clause 18 (representations) of the Facility Agreement, as amended and supplemented by this Agreement and updated with appropriate modifications to refer to this Agreement, by
reference to the circumstances then existing on the date of this Agreement. 
  

	4.2	Finance Document representations 

 Each Obligor makes the representations and warranties
set out in the Finance Documents (other than the Facility Agreement) to which it is a party, as amended and supplemented by this Agreement and updated with appropriate modifications to refer to this Agreement, by reference to the circumstances then
existing on the date of this Agreement. 
  

	5	AMENDMENTS TO FACILITY AGREEMENT AND OTHER FINANCE DOCUMENTS 

  

	5.1	Specific amendments to the Facility Agreement 

 With effect on and from the Effective
Date the Facility Agreement shall be, and shall be deemed by this Agreement to be, amended as follows: 
  

	(a)	By deleting clause 20.3 of the Facility Agreement and replacing it with the new clause 20.3: 

“ASC shall at all times during the Security Period on a consolidated basis maintain: 

(a) a minimum Solvency of at least 30 per cent.; 

(b) minimum Cash of an amount the greater of: 

(i) $750,000 per Fleet Vessel; and 

(ii) 5 per cent. of the Total Consolidated Long Term Debt; 

(c) a positive Working Capital excluding balloon maturities; and 

(d) a ratio of EBITDA plus one third of cash in excess of minimum Cash to Total Interest Expenses, computed on a trailing 4 quarter basis shall
at all times exceed 2.25:1.0; and 
 (e) Minimum Adjusted Net Worth of not less than $150,000,000. 

The financial covenants contained in this Clause 20.3 shall be tested semi-annually on the basis of the annual and semi-annual financial
statements provided under Clause 19.2 and shall be confirmed in the relevant Compliance Certificate referred to in Clause 19.3.” 
  

	(b)	By deleting clause 20.4 of the Facility Agreement and replacing it with the new clause 20.4: 

“The expressions used in this Clause 20 shall be construed in accordance with IFRS, or GAAP as applicable, and for the purposes of this
Agreement: 
 “Cash” means, at any time, cash credited to a bank account in the name of the Borrowers, ASC or a member of
the Group and to which the Borrowers, ASC or a member of the Group is beneficially entitled to and for so long as: 
  

	 	(a)	that cash is repayable on demand; 

  
 3 

	 	(b)	repayment of that cash is not contingent on the prior discharge of any other indebtedness of any member of the Group or of any other person whatsoever or on the satisfaction of any other conditions; 

 

	 	(c)	there is no Security over that cash (although credit balances in the Earnings Accounts and Escrow Accounts or any other account in respect of which there is free access to the credit balance on that account in the
absence of an event of default howsoever described) shall constitute cash for these purposes); and 

 the cash is freely and
immediately available to be applied in repayment or prepayment of the Loan. 
 “Consolidated Equity” means, at any relevant
time, the amount of the total capital reserves of ASC on a consolidated basis as stated is the most recent financial statements of the Group provided in accordance with Clause 19.2 (Financial statements) and determined in accordance with GAAP
or IFRS. 
 “Consolidated Adjusted Total Assets” means the Total Assets adjusted as follows: 

 

	 	(a)	by using the Market Value Adjusted Total Assets value for the Fleet Vessels; and 

  

	 	(b)	by excluding intangible assets (including goodwill but not long-term contract revenue is acquired as part of a business combination). 

“Consolidated Adjusted Total Liabilities” means the Total Consolidated Long Term Debt plus the Total Consolidated Short Term
Debt adjusted as the Facility Agent may consider necessary to reflect the actual financial exposure of ASC and its Subsidiaries. 

“Current Assets” means the current assets of ASC on a consolidated basis as stated in the most recent financial statements of
the Group provided in accordance with Clause 19.2 (Financial statements) and determined in accordance with GAAP or IFRS. 
 “Current
Liabilities” means the current liabilities of ASC on a consolidated basis as stated in the most recent financial statements of the Group provided in accordance with Clause 19.2 (Financial statements) and determined in accordance with
GAAP or IFRS. 
 “EBITDA” means consolidated earnings before interest, taxes depreciation and amortisation. 

“Financial Statements” means the financial statements of ASC provided in accordance with Clause 19.2 (Financial
statements). 
 “Fleet Vessels” means any ship (including the Ships) from time to time wholly owned by the Guarantors
(directly or indirectly) (excluding vessels under construction and vessels chartered in for period shorter than 18 months) (each a “Fleet Vessel”). 

“Fleet Market Value” means in relation to a Fleet Vessel, the Market Value of such Fleet Vessel. 

“Market Value Adjusted Total Assets” means the Total Assets of ASC adjusted in each case for the difference of the book value
of the Fleet Vessels (as evidenced in the most recent Financial Statements) and the Fleet Market Value.” 
 “Minimum Adjusted
Net Worth” means at any relevant time, the amount by which the Consolidated Adjusted Total Assets of the Group exceed the Consolidated Adjusted Total Liabilities of the Group. 

  
 4 

 “Solvency” means Consolidated Equity to Market Value Adjusted Total Assets. 

“Total Assets” means, in respect of ASC, the amount of total assets of ASC at any time on a consolidated basis which would be
included in the applicable Financial Statements for ASC as total assets determined in accordance with IFRS or GAAP as applicable. 

“Total Consolidated Long Term Debt” means, in respect of ASC, the amount of total liabilities of ASC (as such term is defined
in the applicable Financial Statements of ASC and including without limitation any liability in respect of any lease or hire purchase contract) at any time on a consolidated basis which would be included in the applicable Financial Statements of ASC
as total long term debt in accordance with IFRS or GAAP as applicable, including the current portion of long term debt (as such term is defined in the applicable Financial Statements for ASC). 

“Total Consolidated Short Term Debt” means, at any relevant time, the amount of the total liabilities of ASC on a consolidated
basis which would be included in the applicable Financial Statements of ASC as total short term debt in accordance with GAAP or IFRS including the current portion of short term debt. 

“Total Interest Expenses” means, in respect of any period and at any relevant time, the aggregate (calculated on a
consolidated basis of ASC) of: 
  

	 	(a)	the amounts charged and posted (or estimated to be charged and posted) as a current accrual accrued during such period by way of interest on all financial indebtedness in accordance with GAAP or IFRS; and

  

	 	(b)	net payments in relation to interest rate hedging arrangements in respect of financial indebtedness in accordance with GAAP or IFRS (after deducting net income in relation to such interest rate hedging arrangements).

 “Working Capital” means the Current Assets less the Current Liabilities.” 

 

	(c)	the definition of, and references throughout to, each Finance Document shall be construed as if the same referred to that Finance Document as amended and supplemented by this Agreement; and 

 

	(d)	by construing references throughout to “this Agreement” and other like expressions as if the same referred to the Facility Agreement as amended and supplemented by this Agreement. 

 

	5.2	Amendments to Finance Documents 

 With effect on and from the Effective Date each of the
Finance Documents other than the Facility Agreement, shall be, and shall be deemed by this Agreement to be, amended as follows: 
  

	(a)	the definition of, and references throughout each of the Finance Documents to, the Facility Agreement and any of the other Finance Documents shall be construed as if the same referred to the Facility Agreement and those
Finance Documents as amended and supplemented by this Agreement; and 

  

	(b)	by construing references throughout each of the Finance Documents to “this Agreement”, “this Deed” and other like expressions as if the same referred to such Finance Documents as amended and
supplemented by this Agreement. 

  

	5.3	Finance Documents to remain in full force and effect 

 The Finance Documents shall remain
in full force and effect as amended and supplemented by: 

  
 5 

	(a)	the amendments to the Finance Documents contained or referred to in Clause 5.1 (Specific amendments to the Facility Agreement) and Clause 5.2 (Amendments to Finance Documents); and 

 

	(b)	such further or consequential modifications as may be necessary to give full effect to the terms of this Agreement. 

  

	6	FURTHER ASSURANCE 

  

	6.1	Further assurance 

  

	(a)	Each Obligor shall (and the Guarantors shall procure that each member of the Group and any Obligor not a party to this Agreement will) promptly, and in any event within the time period specified by the Facility Agent do
all such acts (including procuring or arranging any registration, notarisation or authentication or the giving of any notice) or execute or procure execution of all such documents (including assignments, transfers, mortgages, charges, notices,
instructions, acknowledgements, proxies and powers of attorney), as the Facility Agent may specify (and in such form as the Facility Agent may require in favour of the Facility Agent or its nominee(s)) to implement the terms and provisions of this
Agreement. 

  

	(b)	Each Obligor shall (and the Guarantors shall procure that each member of the Group and any Obligor not a party to this Agreement will) promptly, and in any event within the time period specified by the Security Agent do
all such acts (including procuring or arranging any registration, notarisation or authentication or the giving of any notice) or execute or procure execution of all such documents (including assignments, transfers, mortgages, charges, notices,
instructions, acknowledgments, proxies and powers of attorney), as the Security Agent may specify (and in such form as the Security Agent may require in favour of the Security Agent or its nominee(s)): 

 

	 	(i)	to create, perfect, vest in favour of the Security Agent or protect the priority of the Security or any right or any kind created or intended to be created under or evidenced by the Finance Documents as amended and
supplemented by this Agreement (which may include the execution of a mortgage, charge, assignment or other Security over all or any of the assets which are, or are intended to be, the subject of the Transaction Security) or for the exercise of any
rights, powers and remedies of the Security Agent, any Receiver or the Secured Parties provided by or pursuant to the Finance Documents as amended and supplemented by the Agreement or by law; 

 

	 	(ii)	to confer on the Security Agent or confer on the Secured Parties Security over any property and assets of that Obligor located in any jurisdiction equivalent or similar to the Security intended to be conferred by or
pursuant to the Finance Documents as amended and supplemented by this Agreement; 

  

	 	(iii)	to facilitate or expedite the realisation and/or sale of, the transfer of title to or the grant of, any interest in or right relating to the assets which are, or are intended to be, the subject of the Transaction
Security or to exercise any power specified in any Finance Document as amended and supplemented by this Agreement in respect of which the Security has become enforceable; and/or 

 

	 	(iv)	to enable or assist the Security Agent to enter into any transaction to commence, defend or conduct any proceedings and/or to take any other action relating to any item of the Security Property. 

 

	(c)	 Each Obligor shall, (and the Guarantors shall procure that each member of the Group will) take all such action as is available to it (including making
all filings and registrations) as may be necessary for the purpose of the creation, perfection, protection or maintenance of any Security conferred or intended to be conferred on the Security Agent or the Secured Parties by or pursuant to the
Finance Documents as amended and supplemented by this Agreement. 

  
 6 

	6.2	Additional corporate action 

 At the same time as an Obligor delivers to the Facility
Agent or Security Agent any document executed under this Clause 6 (Further Assurance), that Obligor shall deliver to the Facility Agent or Security Agent as applicable a certificate signed by two of that Obligor’s directors or officers
which shall: 
  

	(a)	set out the text of a resolution of that Obligor’s directors specifically authorising the execution of the document specified by the Facility Agent or the Security Agent as applicable; and 

 

	(b)	state that either the resolution was duly passed at a meeting of the directors validly convened and held, throughout which a quorum of directors entitled to vote on the resolution was present, or that the resolution has
been signed by all the directors of officers and is valid under that Obligor’s articles of association or other constitutional documents. 

  

	7	COSTS AND EXPENSES 

 Clause 16.2 (amendment costs) of the Facility Agreement, as
amended and supplemented by this Agreement, applies to this Agreement as if it were expressly incorporated in it with any necessary modifications. 
  

	8	NOTICES 

 Clause 36 (notices) of the Facility Agreement, as amended and
supplemented by this Agreement, applies to this Agreement as if it were expressly incorporated in it with any necessary modifications. 
  

	9	COUNTERPARTS 

 This Agreement may be executed in any number of counterparts, and this has
the same effect as if the signatures on the counterparts were on a single copy of this Agreement. 
  

	10	GOVERNING LAW 

 This Agreement and any non-contractual obligations arising out of or in
connection with it are governed by English law. 
  

	11	ENFORCEMENT 

  

	11.1	Jurisdiction 

  

	(a)	The courts of England have exclusive jurisdiction to settle any dispute arising out of or in connection with this Agreement (including a dispute regarding the existence, validity or termination of this Agreement or any
non-contractual obligation arising out of or in connection with this Agreement) (a “Dispute”). 

  

	(b)	The Obligors accept that the courts of England are the most appropriate and convenient courts to settle Disputes and accordingly no Obligor will argue to the contrary. 

 

	11.2	Service of process 

  

	(a)	Without prejudice to any other mode of service allowed under any relevant law, each Obligor (other than an Obligor incorporated in England and Wales): 

 

	 	(i)	irrevocably appoints WFW Legal Services Ltd of 15 Appold Street, London, EC2A 2HB, England as its agent for service of process in relation to any proceedings before the English courts in connection with any Finance
Document; and 

  
 7 

	 	(ii)	agrees that failure by a process agent to notify the relevant Obligor of the process will not invalidate the proceedings concerned. 

  

	(b)	If any person appointed as an agent for service of process is unable for any reason to act as agent for service of process, the Borrowers (on behalf of all the Obligors) must immediately (and in any event within 3 days
of such event taking place) appoint another agent on terms acceptable to the Facility Agent. Failing this, the Facility Agent may appoint another agent for this purpose. 

This Agreement has been entered into on the date stated at the beginning of this Agreement. 

  
 8 

 SCHEDULE 1 

CONDITIONS PRECEDENT 
  

	1	Obligors 

 Documents of the kind specified in Schedule 2 Part A paragraph 1 of the
Facility Agreement. 
  

	2	Legal opinions 

 A legal opinion of the legal advisers to the Arranger, the Facility
Agent and the Security Agent on Marshall Islands law and such other relevant jurisdictions as the Facility Agent may require. 
  

	3	Other documents and evidence 

  

	3.1	A copy of any other Authorisation or other document, opinion or assurance which the Facility Agent considers to be necessary or desirable (if it has notified the Borrowers accordingly) in connection with the entry into
and performance of the transactions contemplated by this Agreement, or for the validity and enforceability of any Finance Document as amended and supplemented by this Agreement. 

 

	3.2	Evidence that the costs and expenses then due from the Borrowers pursuant to Clause 7 (Costs and Expenses) have been paid or will be paid by the Effective Date. 

  
 9 

 EXECUTION PAGES 
  

							
	 BORROWERS
						
				
	 SIGNED by Katharine Langabeer
		)		 /s/ Katharine Langabeer
		
	 duly authorised
		)		Katharine Langabeer		
	 for and on behalf of
		)		Attorney-in-Fact		
	 FASTNET SHIPCO LLC
		)				
	 in the presence of:
		)				
				
	 Witness’ signature:
		)		 /s/ Constance Daws
		
	 Witness’ name:
		)		Constance Daws, Solicitor		
	 Witness’ address:
		)		London EC2A 2HB		
				
	 SIGNED by Katharine Langabeer
		)		 /s/ Katharine Langabeer
		
	 duly authorised
		)		Katharine Langabeer		
	 for and on behalf of
		)		Attorney-in-Fact		
	 SHANNON SHIPCO LLC
		)				
	 in the presence of:
		)				
				
	 Witness’ signature:
		)		 /s/ Constance Daws
		
	 Witness’ name:
		)		Constance Daws, Solicitor		
	 Witness’ address:
		)		London EC2A 2HB		
				
	 SIGNED by Katharine Langabeer
		)		 /s/ Katharine Langabeer
		
	 duly authorised
		)		Katharine Langabeer		
	 for and on behalf of
		)		Attorney-in-Fact		
	 ROCKALL SHIPCO LLC
		)				
	 in the presence of:
		)				
				
	 Witness’ signature:
		)		 /s/ Constance Daws
		
	 Witness’ name:
		)		Constance Daws, Solicitor		
	 Witness’ address:
		)		London EC2A 2HB		

  
 10 

							
	 SIGNED by Katharine Langabeer
		)		 /s/ Katharine Langabeer
		
	 duly authorised
		)		Katharine Langabeer		
	 for and on behalf of
		)		Attorney-in-Fact		
	 FORTH SHIPCO LLC
		)				
	 in the presence of:
		)				
				
	 Witness’ signature:
		)		 /s/ Constance Daws
		
	 Witness’ name:
		)		Constance Daws, Solicitor		
	 Witness’ address:
		)		London EC2A 2HB		
				
	 SIGNED by Katharine Langabeer
		)		 /s/ Katharine Langabeer
		
	 duly authorised
		)		Katharine Langabeer		
	 for and on behalf of
		)		Attorney-in-Fact		
	 VIKING SHIPCO LLC
		)				
	 in the presence of:
		)				
				
	 Witness’ signature:
		)		 /s/ Constance Daws
		
	 Witness’ name:
		)		Constance Daws, Solicitor		
	 Witness’ address:
		)		London EC2A 2HB		
				
	GUARANTORS						
				
	 SIGNED by Katharine Langabeer
		)		 /s/ Katherine Langabeer
		
	 duly authorised
		)		Katharine Langabeer		
	 for and on behalf of
		)		Attorney-in-Fact		
	 ARDMORE SHIPPING CORPORATION
		)				
	 in the presence of:
		)				
				
	 Witness’ signature:
		)		 /s/ Constance Daws
		
	 Witness’ name:
		)		Constance Daws, Solicitor		
	 Witness’ address:
		)		London EC2A 2HB		

  
 11 

							
	SIGNED by Katharine Langabeer		)		 /s/ Katharine Langabeer
		
	duly authorised		)		Katharine Langabeer		
	for and on behalf of		)		Attorney-in-Fact		
	ARDMORE SHIPPING LLC		)				
	in the presence of:		)				
				
	Witness’ signature:		)		 /s/ Constance Daws
		
	Witness’ name:		)		Constance Daws, Solicitor		
	Witness’ address:		)		London EC2A 2HB		
				
	ORIGINAL LENDER						
				
	SIGNED by Emeline Yew		)		 /s/ Emeline Yew
		
	duly authorised		)		Emeline Yew		
	for and on behalf of		)		Attorney-in-Fact		
	DVB BANK SE		)				
	in the presence of:		)				
				
	Witness’ signature:		)		 /s/ Constance Daws
		
	Witness’ name:		)		Constance Daws, Solicitor		
	Witness’ address:		)		London EC2A 2HB		
				
	FACILITY AGENT						
				
	SIGNED by Emeline Yew		)		 /s/ Emeline Yew
		
	duly authorised		)		Emeline Yew		
	for and on behalf of		)		Attorney-in-Fact		
	DVB BANK SE		)				
	in the presence of:		)				
				
	Witness’ signature:		)		 /s/ Constance Daws
		
	Witness’ name:		)		Constance Daws, Solicitor		
	Witness’ address:		)		London EC2A 2HB		

  
 12 

							
	SECURITY AGENT		 		 		 
				
	SIGNED by Emeline Yew		)		 /s/ Emeline Yew
		 
	 duly authorised
		)		Emeline Yew		
	 for and on behalf of
		)		Attorney-in-Fact		
	 DVB BANK SE
		)				
	 in the presence of:
		)				
				
	 Witness’ signature:
		)		 /s/ Constance Daws
		
	 Witness’ name:
		)		Constance Daws, Solicitor		
	 Witness’ address:
		)		London EC2A 2HB		

  
 13Exhibit 4.1

 

NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON THE EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED, OR BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT, OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF SUCH SECURITIES BY ANY PERSON FOR A PERIOD OF ONE HUNDRED AND EIGHTY (180) DAYS IMMEDIATELY FOLLOWING MARCH [27], 2015, AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, EXCEPT IN ACCORDANCE WITH FINRA RULE 5110(G)(2).

 

APPLIED DNA SCIENCES, INC.

 

COMMON STOCK PURCHASE WARRANT

	  	  	
Original Issue Date: April [1], 2015

 

Applied DNA Sciences, Inc., a Delaware corporation (the “Company”), hereby certifies that, as partial compensation for its services as underwriter to the Company, Maxim Group LLC, or its registered assigns (the “Holder”), is entitled to purchase from the Company up to a total of _____________ number of shares of Common Stock (each, a “Warrant” and collectively, the “Warrants,” and each such share of Common Stock, a “Warrant Security” and all such shares of Common Stock, the “Warrant Securities”), at any time and from time to time after the 180th day following March [27], 2015 and through and including, March [27], 2020, the fifth anniversary of such effective date (the “Expiration Date”), in accordance with FINRA Rule 5110(f)(2)(G)(i), and subject to the following terms and conditions:

 

1. Definitions. As used in this Warrant, the following terms shall have the respective definitions set forth in this Section 1. Other capitalized terms used and not otherwise defined shall have the meanings set forth in that certain Underwriting Agreement, dated March [27], 2015, between the Company and the Holder.

 

“Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 144.

 

“Business Day” means any day except Saturday, Sunday and any day which is a federal legal holiday or a day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

 

    	1

    	 

    
 

 

“Common Stock” means the common stock of the Company, $0.001 par value per share, and any securities into which such common stock may hereafter be reclassified or for which it may be exchanged as a class.

 

“Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

“Exercise Price” means $____ (115% of the public offering price in connection with the Offering), subject to adjustment in accordance with Section 9.

 

“Fundamental Transaction” means any of the following: (1) the Company effects any merger or consolidation of the Company with or into another Person, (2) the Company effects any sale of all or substantially all of its assets in one or a series of related transactions, (3) any tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property, or (4) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property.

 

“New York Courts” means the state and federal courts sitting in the City of New York, Borough of Manhattan.

 

“Original Issue Date” means the Original Issue Date first set forth on the first page of this Warrant.

 

“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

 “Rule 144” means Rule 144 promulgated by the Securities and Exchange Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Securities and Exchange Commission having substantially the same effect as such Rule.

 

“Securities Act” means the Securities Act of 1933, as amended.

 

“Subsidiary” means any “significant subsidiary” as defined in Rule 1-02(w) of Regulation S-X promulgated by the Securities and Exchange Commission under the Exchange Act.

“Trading Day” means (i) a day on which the Common Stock is traded on a Trading Market, or (ii) if the Common Stock is not quoted on any Trading Market, a day on which the Common Stock is quoted in the over-the-counter market as reported by OTC Markets Group Inc. (or any similar organization or agency succeeding to its functions of reporting prices); provided, that in the event that the Common Stock is not listed or quoted as set forth in (i) or (ii) hereof, then Trading Day shall mean a Business Day.

 

“Trading Market” means whichever of the New York Stock Exchange, the NYSE MKT, the NASDAQ Global Select Market, the NASDAQ Global Market, the NASDAQ Capital Market or the OTC Bulletin Board on which the Common Stock is listed or quoted for trading on the date in question.

 

    	2

    	 

    
 

 

2. Registration of Warrant. The Company shall register this Warrant upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

3. Registration of Transfers. The Company shall register the transfer of any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, with the Form of Assignment attached hereto duly completed and signed, to the Company at its address specified herein. Upon any such registration or transfer, a new Warrant to purchase Warrant Securities in substantially the form of this Warrant (any such new Warrant, a “New Warrant”), evidencing the portion of this Warrant so transferred shall be issued to the transferee and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations of a holder of a Warrant.

 

4. Exercise and Duration of Warrants. This Warrant shall be exercisable by the registered Holder at any time and from time to time from and after 181 days following March [27], 2015 (the “Sale Commencement Date”), through and including the Expiration Date in accordance with FINRA Rule 5110(f)(2)(G)(i). At 5:00 p.m., Eastern Standard Time on the Expiration Date, the portion of this Warrant not exercised prior thereto shall be and become void and of no value. The Company may not call or redeem any portion of this Warrant without the prior written consent of the affected Holder. In accordance with FINRA Rule 5110(g)(1), this Warrant shall not be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of this Warrant by any person for a period of 180 days immediately following the Sale Commencement Date, except as provided in FINRA Rule 5110(g)(2).

 

5. Delivery of Warrant Securities.

 

(a) Upon delivery of the Exercise Notice (in the form attached hereto) to the Company (with the attached Warrant Exercise Log) at its address for notice set forth herein and upon payment of the Exercise Price multiplied by the number of Warrant Securities that the Holder intends to purchase hereunder, the Company shall promptly (but in no event later than three Trading Days after the Date of Exercise (as defined herein)) issue and deliver to the Holder, a certificate for the Warrant Securities issuable upon such exercise. The Company shall, upon request of the Holder and subsequent to the date on which a registration statement covering the resale of the Warrant Securities has been declared effective by the Securities and Exchange Commission, use its reasonable best efforts to deliver Warrant Securities hereunder electronically through the Depository Trust Corporation or another established clearing corporation performing similar functions, if available, provided, that, the Company may, but will not be required to change its transfer agent if its current transfer agent cannot deliver Warrant Securities electronically through the Depository Trust Corporation. A “Date of Exercise” means the date on which the Holder shall have delivered to the Company: (i) the Exercise Notice (with the Warrant Exercise Log attached to it), appropriately completed and duly signed and (ii) payment of the Exercise Price for the number of Warrant Securities so indicated by the Holder to be purchased.

 

(b) If by the third Trading Day after a Date of Exercise the Company fails to deliver the required number of Warrant Securities in the manner required pursuant to Section 5(a), then the Holder will have the right to rescind such exercise.

 

    	3

    	 

    
 

 

(c) If by the third Trading Day after a Date of Exercise the Company fails to deliver the required number of Warrant Securities in the manner required pursuant to Section 5(a), and if after such third Trading Day and prior to the receipt of such Warrant Securities, the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Securities which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (1) pay in cash to the Holder the amount by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (A) the number of Warrant Securities that the Company was required to deliver to the Holder in connection with the exercise at issue by (B) the closing bid price of the Common Stock on the Date of Exercise and (2) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Securities for which such exercise was not honored or deliver to the Holder the number of shares of Common Stock or Warrants that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In, and, upon request, of the Company, evidence of the amount of such loss.

 

(d) The Company’s obligations to issue and deliver Warrant Securities in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Securities. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing Warrant Securities upon exercise of the Warrant as required pursuant to the terms hereof.

 

6. Charges, Taxes and Expenses. Issuance and delivery of Warrant Securities upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, withholding tax, transfer agent fee or other incidental tax or expense in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the registration of any certificates for Warrant Securities or Warrants in a name other than that of the Holder. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Securities upon exercise hereof.

 

7. Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary and reasonable indemnity (which shall not include a surety bond), if requested. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company’s obligation to issue the New Warrant.

 

    	4

    	 

    
 

 

8. Reservation of Warrant Securities. The Company covenants that it will at all times reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved shares of Common Stock solely for the purpose of enabling it to issue Warrant Securities upon exercise of this Warrant as herein provided, the number of shares of Common Stock which are then issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of Persons other than the Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Securities so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly authorized, validly issued and fully paid and non-assessable.

 

9. Certain Adjustments. The Exercise Price and number of Warrant Securities issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section 9.

 

(a) Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock, (ii) subdivides outstanding shares of Common Stock into a larger number of shares, or (iii) combines outstanding shares of Common Stock into a smaller number of shares, then in each such case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, and any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or combination.

 

(b) Fundamental Transactions. If, at any time while this Warrant is outstanding there is a Fundamental Transaction, then the Holder shall have the right thereafter to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Securities then issuable upon exercise in full of this Warrant (the “Alternate Consideration”). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. At the Holder’s option and request, any successor to the Company or surviving entity in such Fundamental Transaction shall issue to the Holder a new warrant substantially in the form of this Warrant and consistent with the foregoing provisions and evidencing the Holder’s right to purchase the Alternate Consideration for the aggregate Exercise Price upon exercise thereof. The terms of any agreement pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this paragraph (b) and insuring that the Warrant (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction.

 

(c) Adjustments for Other Distributions. In the event the Company shall declare a distribution on the outstanding Common Stock that is payable in securities of other Persons, evidences of indebtedness issued by the Company or other Persons, assets (excluding cash dividends or distributions to the holders of Common Stock paid out of current or retained earnings and declared by the Company’s Board of Directors) or options or rights, then, in each such case for the purpose of this Section 9(c), upon exercise of this Warrant, the Holder shall be entitled to a proportionate share of any such distribution as though the Holder was the actual record holder of the number of shares of Common Stock which might have been purchased upon exercise of this Warrant immediately prior to the record date fixed for the determination of the holders of Common Stock of the Company entitled to receive such distribution (or the date of such distribution if no record date is fixed).

 

    	5

    	 

    
 

 

(d) Subsequent Rights Offering. In addition to any adjustments pursuant to Section 9(c) above, if at any time during which this Warrant is outstanding, the Company grants, issues or sells any Common Stock equivalents or other rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, beneficial ownership limitations) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding beneficial ownership limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding beneficial ownership limitations). The provisions of this Section 9(d) will not apply to any grant, issuance or sale of Common Stock equivalents or other rights to purchase stock, warrants, securities or other property of the Company which is not made pro rata to the record holders of any class of shares of Common Stock.

 

(e) Number of Warrant Securities. Simultaneously with any adjustment to the Exercise Price pursuant to this Section 9, the number of Warrant Securities that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the adjusted number of Warrant Securities shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment.

 

(f) Calculations. All calculations under this Section 9 shall be made to the nearest cent or the nearest 1/100th of a share, as applicable. The number of shares of Common Stock outstanding at any given time shall not include shares owned or held by or for the account of the Company, and the disposition of any such shares shall be considered an issue or sale of Common Stock.

 

(g) Notice of Adjustments. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will promptly compute such adjustment in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Securities or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company’s Transfer Agent.

 

    	6

    	 

    
 

 

(h) Notice of Corporate Events. If the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including without limitation any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any Subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then the Company shall deliver to the Holder a notice describing the material terms and conditions of such transaction (but only to the extent such disclosure would not result in the dissemination of material, non-public information to the Holder) at least 10 calendar days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction, and the Company will take all steps reasonably necessary in order to insure that the Holder is given the practical opportunity to exercise this Warrant prior to such time so as to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice.

 

10. Payment of Exercise Price. The Holder may pay the Exercise Price in one of the following manners:

 

(a) Cash Exercise. The Holder may deliver immediately available funds; or

 

(b) Cashless Exercise. If on the Date of Exercise there is no effective registration statement registering, or the prospectus contained therein is not available for, the resale of the Warrant Securities, the Holder may notify the Company in an Exercise Notice of its election to utilize cashless exercise, in which event the Company shall issue to the Holder the number of Warrant Securities determined as follows:

 

X = Y [(A-B)/A]

 

where:

X = the number of Warrant Securities to be issued to the Holder.

 

Y = the number of Warrant Securities with respect to which this Warrant is being exercised.

 

A = the average of the daily volume weighted average price of the Common Stock for the five Trading Days immediately prior to (but not including) the Date of Exercise.

 

B = the Exercise Price.

 

For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Securities issued in a cashless exercise transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Securities shall be deemed to have commenced, on the date this Warrant was originally issued.

 

    	7

    	 

    
 

 

11. Limitations on Exercise. Notwithstanding anything to the contrary contained herein, the number of Warrant Securities that may be acquired by the Holder upon any exercise of this Warrant (or otherwise in respect hereof) shall be limited to the extent necessary to insure that, following such exercise (or other issuance), the total number of shares of Common Stock then beneficially owned by such Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act, does not exceed 9.99% of the total number of issued and outstanding shares of Common Stock (including for such purpose the shares of Common Stock issuable upon such exercise). For such purposes, beneficial ownership shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. To the extent that the limitation contained in this Section 11 applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of an Exercise Notice shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable, in each case subject the limitation contained in this Section 11, and the Company shall have no obligation to verify or confirm the accuracy of such determination. This provision shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section 9 of this Warrant. This restriction may not be waived. Notwithstanding anything to the contrary contained in this Warrant, (a) no term of this Section may be waived by any party, nor amended such that the threshold percentage of ownership would be directly or indirectly increased, (b) this restriction runs with the Warrant and may not be modified or waived by any subsequent holder hereof and (c) any attempted waiver, modification or amendment of this Section will be void ab initio.

 

12. No Fractional Shares. No fractional Warrant Securities will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares which would, otherwise be issuable, the Company shall pay cash equal to the product of such fraction multiplied by the closing price of one share of Common Stock as reported by the applicable Trading Market on the date of exercise.

 

13. Registration Rights.

 

(a) Demand Registration. The Company, upon written demand (a “Demand Notice”) by the Holder, and if the Holder has assigned a portion of the Warrant, of the holders, agrees to register (a “Demand Registration”), on one occasion, all or any portion of the Warrant Securities. On such occasion, the Company will file a registration statement or a post-effective amendment to the Registration Statement covering the Warrant Securities within sixty (60) days after receipt of a Demand Notice and use its best efforts to have such registration statement or post-effective amendment declared effective promptly thereafter, subject to compliance with review by the Commission; provided, however, that the Company shall not be required to comply with a Demand Notice if the Company has filed a registration statement with respect to which the Holder is entitled to piggyback registration rights pursuant to Section 13(b) hereof and either: (i) the Holder was given the opportunity to exercise its rights under Section 13(b) hereof in connection with the offering covered by such registration statement or (ii) if such registration statement relates to an underwritten primary offering of securities of the Company, until the offering covered by such registration statement has been withdrawn or until thirty (30) days after such offering is consummated. A Demand Notice may be given at any time during the period of four and a half (4.5) years beginning 180 days from the Sale Commencement Date. The Company covenants and agrees, if the Holder has assigned a portion of this Warrant, to give written notice of its receipt of the Demand Notice by any Holder to all other registered Holder of the Warrants and/or the Warrant Securities within ten (10) days from the date of the receipt of such Demand Notice. The Holder, or if the Warrant has been assigned, the Holders, shall not effect more than two (2) Demand Registrations pursuant to this Section 13(a). A registration will not count as a Demand Registration until the registration statement filed with the Commission with respect to such Demand Registration has been declared effective and the Company has complied with all of its obligations under hereunder with respect thereto; provided, however, that if, after such registration statement has been declared effective, the offering of the Warrant Securities pursuant to a Demand Registration is interfered with by any stop order or injunction of the Commission or any other governmental agency or court, the registration statement with respect to such Demand Registration will be deemed not to have been declared effective, unless and until, (i) such stop order or injunction is removed, rescinded or otherwise terminated, and (ii) the Holder thereafter elect to continue the offering. The Company shall bear all fees and expenses attendant to the first Demand Registration pursuant to Section 13(a), including the reasonable and documented expenses of a single legal counsel selected by the Holders to represent them in connection with the sale of the Warrant Securities, but the Holders shall pay any and all underwriting commissions or brokerage fees related to the Warrant Securities, if applicable. The Holders shall bear all fees and expenses (including all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent them) in connection with the second Demand Registration pursuant to Section 13(a). The Company agrees to use its best efforts to cause the filing required herein to become effective promptly and to qualify or register the Warrant Securities in such States as are reasonably requested by the Holder, or if the Warrant has been assigned, by the Holders; provided, however, that in no event shall the Company be required to register the Warrant Securities in a State in which such registration would cause: (i) the Company to be obligated to register or license to do business in such State or submit to general service of process in such State, or (ii) the principal stockholders of the Company to be obligated to escrow their shares of capital stock of the Company. The Company shall use its commercially reasonable efforts to cause any registration statement filed pursuant to the demand right granted under Section 13(a) to remain effective for a period of at least twelve (12) consecutive months from the date that the Holder of the Warrant Securities covered by such registration statement are first given the opportunity to sell all of such securities. The Holder shall only use the prospectuses provided by the Company to sell the shares covered by such registration statements, and will immediately cease to use any prospectus furnished by the Company if the Company advises the Holder that such prospectus may no longer be used due to a material misstatement or omission.

 

    	8

    	 

    
 

 

(b) “Piggy-Back” Registration. In addition to the demand rights of registration described in Section 13(a) hereof, the Holder shall have the right, for a period of five (5) years commencing 180 days from the Sale Commencement Date, to include the Warrant Securities as part of any other registration of securities filed by the Company (other than in connection with a transaction contemplated by Rule 145(a) promulgated under the Securities Act or pursuant to Form S-8 or S-4 or any equivalent form); provided, however, that if, solely in connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s) thereof shall, in its reasonable discretion, impose a limitation on the number of Warrant Securities which may be included in the registration statement because, in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such registration statement only such limited portion of the Warrant Securities with respect to which the Holder requested inclusion hereunder as the underwriter(s) shall reasonably permit. Any exclusion of Warrant Securities shall be made pro rata among the Holder, or if the Warrant has been assigned, to the Holders seeking to include Warrant Securities in proportion to the number of Warrant Securities sought to be included by such Holders; provided, however, that the Company shall not exclude any Warrant Securities unless the Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities in such registration statement or are not entitled to pro rata inclusion with the Warrant Securities. The Holders shall be entitled to unlimited piggy-back registration rights pursuant to this Section 13(b). Any holder of the Warrant Securities may elect to withdraw such Holder’s request for inclusion of the Warrant Securities in any piggy-back registration by giving written notice to the Company of such request to withdraw prior to the effectiveness of the registration statement. The Company (whether on its own determination or as the result of a withdrawal by persons making a demand pursuant to written contractual obligations) may withdraw a registration statement at any time prior to the effectiveness of the registration statement. Notwithstanding any such withdrawal, the Company shall pay all expenses incurred by the Holders of the Warrant Securities in connection with such piggy-back registration as provided in Section 13(b). The Company shall bear all fees and expenses attendant to registering the Warrant Securities pursuant to Section 13(b) hereof, including the reasonable and documented expenses of a single legal counsel selected by the Holders to represent them in connection with the sale of the Warrant Securities, but the Holders shall pay any and all underwriting commissions or brokerage fees related to the Warrant Securities. In the event of such a proposed registration, the Company shall furnish the then Holders of outstanding Warrant Securities with not less than fifteen (15) days written notice prior to the proposed date of filing of such registration statement. Such notice to the Holders shall continue to be given for each registration statement filed by the Company until such time as all of the Warrant Securities have been sold by the Holder. The holders of the Warrant Securities shall exercise the “piggy-back” rights provided for herein by giving written notice, within ten (10) days of the receipt of the Company’s notice of its intention to file a registration statement. The Company shall use its best efforts to cause any registration statement filed pursuant to the piggyback right granted under Section 13(b) to remain effective for a period of at least nine (9) consecutive months from the date that the Holders of the Warrant Securities covered by such registration statement are first given the opportunity to sell all of such securities.

 

    	9

    	 

    
 

 

14. Notices. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number specified in this Section prior to 5:00 p.m. (Eastern Standard Time) on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number specified in this Section on a day that is not a Trading Day or later than 6:30 p.m. (Eastern Standard Time) on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. The addresses for such communications shall be: (i) if to the Company, to Applied DNA Sciences, Inc., 50 Health Sciences Drive, Stony Brook, New York 11790, Attention: Chief Executive Officer (or such other address as the Company shall indicate in writing in accordance with this Section), or via facsimile to (631) 240-8900, or (ii) if to the Holder, to the address or facsimile number appearing on the Warrant Register or such other address or facsimile number as the Holder may provide to the Company in accordance with this Section.

 

15. Miscellaneous.

 

(a) This Warrant shall be binding on and inure to the benefit of the parties hereto and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder and their successors and assigns. The foregoing sentence shall be subject to the restrictions on waivers and amendments set forth in Section 11 of this Warrant.

 

(b) The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

    	10

    	 

    
 

 

 (c) All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of this Warrant and the transactions herein contemplated (“Proceedings”) (whether brought against a party hereto or its respective Affiliates, employees or agents) shall be commenced exclusively in the New York Courts. Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any Proceeding, any claim that it is not personally subject to the jurisdiction of any New York Court, or that such Proceeding has been commenced in an improper or inconvenient forum. Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Warrant or the transactions contemplated hereby. If either party shall commence a Proceeding to enforce any provisions of this Warrant, then the prevailing party in such Proceeding shall be reimbursed by the other party for its attorney’s fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Proceeding.

 

(d) The failure of any of the parties hereto to at any time enforce any of the provisions of this Warrant shall not be deemed or construed to be a waiver of any such provision, nor to in any way effect the validity of this Warrant or any provision hereof or the right of any of the parties hereto to thereafter enforce each and every provision of this Warrant. No waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Warrant shall be effective unless set forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.

 

(e) The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.

 

(f) In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby and the parties will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant.

 

(g) Prior to exercise of this Warrant, the Holder hereof shall not, by reason of being a Holder, be entitled to any rights of a stockholder with respect to the Warrant Securities, except as set forth herein.

 

[Signature page follows.]

 

    	11

    	 

    
 

 

IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.

 

	 	APPLIED DNA SCIENCES, INC.
	 	 	 	 
	 	By:	 	 
	 	

Name: James A. Hayward

	 
	 	

Title: Chief Executive Officer

	 

 

    	12

    	 

    
 

 

EXERCISE NOTICE

APPLIED DNA SCIENCES, INC.

WARRANT DATED APRIL [1], 2015

 

The undersigned Holder hereby irrevocably elects to purchase Warrant Securities pursuant to the above referenced Warrant. Capitalized terms used herein and not otherwise defined have the respective meanings set forth in the Warrant.

 

	
(1)

	
The undersigned Holder hereby exercises its right to purchase Warrant Securities pursuant to the Warrant.

	
(2)

	
(PLEASE CHECK ONE METHOD OF PAYMENT)

o The Holder shall pay the sum of $___ to the Company in accordance with the terms of the Warrant; or

 

o The Holder shall exercise the Warrant through a cashless exercise in accordance with the terms of the Warrant.

	 	 
	
(3)

	
Pursuant to this Exercise Notice, the Company shall deliver to the holder Warrant Securities in accordance with the terms of the Warrant.

	 	 
	(4) 	Please issue said Warrant Securities in the name of the undersigned or in such other name as is specified here: ____________________________.
	 	 
	 
(5)

	By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (determined in accordance with Section 13(d) of the Securities Exchange Act of 1934) permitted to be owned under Section 11 of this Warrant to which this notice relates.

 

	
Dated: _____________________

	  	
Name of Holder:

	  	  
	  	  	  
	  	  	
(Print)

	  	  
	  	  	  
	  	  	
Name:

	  	  
	  	  	
Title:

	  	  
	  	  	
Date:

	  	  
	  	  
	  	  	
(Signature must conform in all respects to name of holder as specified on the face of the Warrant.)

 

    	13

    	 

    
 

 

WARRANT EXERCISE LOG

	
Date

	
Number of Warrant

Securities Available to

be Exercised

	
Number of Warrant Securities Exercised

	
Number of Warrant

Securities Remaining

to be Exercised

	  	  	  	  
	  	  	  	  

 

    	14

    	 

    
 

 

APPLIED DNA SCIENCES, INC.

WARRANT DATED APRIL [1], 2015

 

ASSIGNMENT FORM

 

(To assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the warrant.)

 

FOR VALUE RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

_______________________________________________ whose address is

 

_______________________________________________________________.

 

_______________________________________________________________

 

Date: ______________, _______

 

Holder’s Signature: _____________________________

 

Holder’s Address: ______________________________

 

_______________________________

 

Signature Guaranteed: ___________________________________________

 

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.

 

    	15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]